Literature DB >> 4976123

Trasicor in angina pectoris: a double-blind trial.

D F Wilson, O F Watson, J S Peel, A S Turner.   

Abstract

Eighteen patients entered a double-blind trial of the beta-adrenergic blocking drug Trasicor in the treatment of angina pectoris. Six patients had to be withdrawn from the trial when substitution of placebo for Trasicor caused severe exacerbation of angina attacks. In these cases the frequency and severity of angina attacks fell to a minimum when Trasicor was re-established. A further 10 patients were significantly improved by Trasicor. Two patients showed no significant improvement. No side-effects were observed in doses ranging up to 400 mg. daily.

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4976123      PMCID： PMC1982946          DOI： 10.1136/bmj.2.5650.155

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  6 in total

1.  USE OF PROPRANOLOL IN ANGINA PECTORIS.

Authors:  P M GILLAM; B N PRICHARD
Journal:  Br Med J       Date:  1965-08-07

2.  The paradox of beta-adrenergic blockade in hypertension.

Authors:  E D Frohlich; R C Tarazi; H P Dustan; I H Page
Journal:  Circulation       Date:  1968-03       Impact factor: 29.690

3.  Some haemodynamic effects of trasicor (Ciba 39,089-Ba).

Authors:  D F Wilson; O F Watson; J S Peel; R B Langley; A S Turner
Journal:  N Z Med J       Date:  1968-09

4.  Trasicor (39,089/Ba) in angina pectoris. A single-blind trial.

Authors:  D F Wilson; A S Turner
Journal:  N Z Med J       Date:  1968-03

5.  Propranolol-induced depression.

Authors:  H J Waal
Journal:  Br Med J       Date:  1967-04-01

6.  Propranolol and angina pectoris.

Authors:  S Wolfson; R A Heinle; M V Herman; H G Kemp; J M Sullivan; R Gorlin
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778
  6 in total
  11 in total

1.  Beta-adrenergic blocking drugs.

Authors: 
Journal:  Br Med J       Date:  1971-01-30

Review 2.  The syndrome associated with the withdrawal of beta-adrenergic receptor blocking drugs.

Authors:  B N Prichard; R J Walden
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 3.  Central nervous system mechanisms in blood pressure control.

Authors:  A D Struthers; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Effects of a new cardioselective beta-adrenergic blocker (tolamolol) on exercise tolerance in patients with angina pectoris.

Authors:  N K Sood; C W Havard
Journal:  Thorax       Date:  1973-05       Impact factor: 9.139

Review 5.  Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  Drugs       Date:  1974       Impact factor: 9.546

Review 6.  Beta-adrenergic receptor blocking drugs in angina pectoris.

Authors:  B N Prichard
Journal:  Drugs       Date:  1974       Impact factor: 9.546

7.  A 2-year study of the efficacy and tolerability of prenylamine in the treatment of angina pectoris.

Authors:  N Cardoe
Journal:  Postgrad Med J       Date:  1970-12       Impact factor: 2.401

Review 8.  Clinical consequences of abrupt drug withdrawal.

Authors:  C F George; D Robertson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Sep-Oct

9.  Mechanism of action of beta-adrenergic receptor blocking agents in angina pectoris: comparison of action of propranolol with dexpropranolol and practolol.

Authors:  A G Wilson; O G Brooke; H J Lloyd; B F Robinson
Journal:  Br Med J       Date:  1969-11-15

10.  Clinical evaluation of perhexiline maleate in patients with angina pectoris.

Authors:  C J Burns-Cox; K P Chandrasekhar; H Ikram; T H Peirce; J Pilcher; C D Quinlan; J R Rees
Journal:  Br Med J       Date:  1971-12-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.